COVID-19 vaccine
Pfizer have begun testing its COVID-19 vaccine on children under the age of 12, with the trials’ first participants, a pair of nine-year-old twins, being immunised at Duke University on 24 March.
Pfizer intends to enrol 144 children in the first phase of testing, expanding to a 4,500-participant late-stage trial in which they will test the safety, tolerability, and immune response generated by the vaccine, likely by measuring antibody levels in the young subjects.
